Heterozygosity of p21(WAF1/CIP1) enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model

Cell Growth and Differentiation

Volumn 10, Issue 4, 1999, Pages 213-222

  Jones, Jeffrey M ^a   Cui, Xian Shu ^a   Medina, Daniel ^a   Donehower, Lawrence A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; PROTEIN P21; BROXURIDINE; CDKN1A PROTEIN, MOUSE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PHOSPHOTRANSFERASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER MODEL; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; GENE MUTATION; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE; AGE; ALLELE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIVISION; CROSS BREEDING; DOSE RESPONSE; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HETEROZYGOTE; METABOLISM; PATHOLOGY; SERODIAGNOSIS; TIME; TRANSGENIC MOUSE;

AGE FACTORS; ALLELES; ANIMALS; APOPTOSIS; BROMODEOXYURIDINE; CELL DIVISION; CROSSES, GENETIC; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HETEROZYGOTE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHOTRANSFERASES; PRECIPITIN TESTS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032587889     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Elledge, S. J. Cell cycle checkpoints: preventing an identity crisis. Science (Washington DC), 274: 1664-1672, 1996.
2. Hartwell, L. H., and Weinert, T. A. Checkpoints: controls that ensure the order of cell cycle events. Science (Washington DC), 246: 629-634, 1989.
3. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 266: 1821-1828, 1994.
4. Paulovich, A. G., Toczyski, D. P., and Hartwell, L. H. When checkpoints fail. Cell, 88: 315-321, 1997.
5. Lundberg, A. S., and Weinberg, R. A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol., 18: 753-761, 1998.
6. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
7. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
8. 1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
9. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
10. Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L-H., Zhang, P., Dobrowolski, S., Bai, C., Connell-Crowley, L., Swindell, E., Fox, M. P., and Wei, N. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell, 6: 387-400, 1995.
11. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
12. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
13. Johnson, M., Dimitrov, D., Vojta, P. J., Barrett, J. C., Noda, A., Pereira-Smith, O. M., and Smith, J. R. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol. Carcinog., 11: 59-64, 1994.
14. Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., and Jacks, T. P53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev., 9: 935-944, 1995.
15. Parker, S. B., Eichele, G., Zhang, P., Rawls, A., Sands, A. T., Bradley, A., Olson, E. N., Harper, J. W., and Elledge, S. J. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024-1027, 1995.
16. 2/M-phase transition. Mol. Cell. Biol., 18; 546-557, 1998.
17. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol., 18: 629-643, 1998.
18. Bates, S., Ryan, K. M., Phillips, A. C., and Vousden, K. H. Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression. Oncogene, 17: 1691-1703, 1998.
19. 2 arrest after DNA damage. Science (Washington DC), 282: 1497-1501, 1998.
20. Zhang, H., Hannon, G. J., and Beach, D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev., 8: 1750-1758, 1994.
21. LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingertand, J. M., Sandhu, C., Chou, H. S., Fattaey, A., and Harlow, E. New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11: 847-862, 1997.
22. Hengst, L., Gopfert, U., Lashuel, H. A., and Reed, S. I. Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1). Genes Dev., 12: 3882-3888, 1998.
23. WAF1. Cancer Res., 55: 4536-4539, 1995.
24. Yang, Z. Y., Perkins, N. D., Ohno, T., Nabel, E. G., and Nabel, G. J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat. Med., 1: 1052-1056, 1995.
25. Shiohara, M., el-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D. L., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
26. WAF1/CIP1/SDI1 mutant (Arg94 → Trp) identified in a human breast carcinoma. Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. J. Biol. Chem., 271: 15782-15786, 1996.
27. Gao, X., Chen, Y. Q., Wu, N., Grignon, D. J., Sakr, W., Porter, A. T., and Honn, K. V. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene, 11: 1395-1398, 1995.
28. Terry, L. A., Boyd, J., Alcorta, D., Lyon, T., Solomon, G., Hannon, G., Berchuck, A., Beach, D., and Barrett, J. C. Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines. Mol. Carcinog., 16: 221-228, 1996.
29. Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., and Hannon, G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (Lond.), 377: 552-557, 1995.
30. 1 checkpoint control. Cell, 82: 675-684, 1995.
31. Missero, C., Di Cunto, F., Kiyokawa, H., Koff, A., and Paolo Dotto, G. The absence of p21CIP1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev., 10: 3065-3075, 1996.
32. Wang, Y. A., Elson, A., and Leder, P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc. Natl. Acad. Sci. USA, 94: 14590-14595, 1997.
33. Gervais, J. L., Seth, P., and Zhang, H. Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis. J. Biol. Chem., 273: 19207-19212, 1998.
34. Polyak, K., Waldman, T., He, T. C., Kinzler, K. W., and Vogelstein, B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev., 10: 1945-1952, 1996.
35. Tsukamoto, A. S., Grosschedl, R., Guzman, R. C., Parslow, T., and Varmus, H. E. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell, 55: 619-625, 1988.
36. Dunn, T. B. Morphology of mammary tumors in mice. In: F. Homburger (ed.), The Physiopathology of Cancer, pp. 38-84. New York: Hoeber, 1959.
37. Squartini, F., and Pingitore, R. Tumors of the mammary gland. In: V. Turosov and U. Mohr (eds.), Pathology of Tumors in Laboratory Animals, Vol. 2, pp. 47-100. London: Oxford University Press, 1994.
38. Cardiff, R. D. The biology of mammary transgenes: five rules. J. Mamm. Gland Biol. Neoplasia, 1: 61-73, 1996.
39. Cardiff, R. D., and Wellings, S. R. The comparative pathology of human and mouse mammary glands. J. Mamm. Gland Biol. Neoplasia, in press, 1999.
40. Jones, J. M., Attardi, L., Godley, L. A., Laucirica, R., Medina, D., Jacks, T., Varmus, H. E., and Donehower, L. A. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ., 8: 829-838, 1997.
41. Donehower, L. A., Godley, L. A., Aldaz, C. M., Pyle, R., Shi, Y. P., Pinkel, D., Gray, J., Bradley, A., Medina, D., and Varmus, H. E. Deficiency of p53 accelerates mammary tumorigenesis in WnT-1 transgenic mice and promotes chromosomal instability. Genes Dev., 9: 882-895, 1995.
42. Gorospe, M., Cirielli, C., Wang, X., Seth, P., Capogrossi, M. C., and Holbrook, N. J. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene, 14: 929-935, 1997.
43. Olson, M. F., Paterson, H. F., and Marshall, C. J. Signals from Ras and Rho GTPases interact to regulate expression of p21Wafl/Cip1. Nature (Lond.), 394: 295-299, 1998.
44. Sewing, A. B., Wiseman, B., Lloyd, A. C., and Land, H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol., 17: 5588-5597, 1997.
45. Dietrich, W. F., Lander, E. S., Smith, J. S., Moser, A. R., Gould, K. A., Luongo, C., Borenstein, N., and Dove, W. F. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell, 75: 631-639, 1993.
46. Bilger, A., Shoemaker, A. R., Gould, K. A., and Dove, W. F. Manipulation of the mouse germline in the study of Min-induced neoplasia. Semin. Cancer Biol., 7: 249-260, 1996.
47. Demetrick, D. J., Matsumoto, S., Hannon, G. J., Okamoto, K., Xiong, Y., Zhang, H., and Beach, D. Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3). Cytogenet. Cell Genet., 69: 190-192, 1995.
48. Foulkes, W. D., Ragoussis, J., Stamp, G. W., Allan, G. J., and Trowsdale, J. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br. J. Cancer, 67: 551-559, 1993.
49. Schwerdtle, R. F., Storkel, S., Neuhaus, C., Brauch, H., Weidt, E., Brenner, W. R., Hohenfellner, R., Huber, C., and Decker, H. J. Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma. Cancer Res., 56: 2927-2930, 1996.
50. Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., and Kato, J-Y. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol., 14: 2066-2076, 1994.
51. Miller, B. E., Miller, F. R., Wibum, D., and Heppner, G. H. Dominance of a tumor subpopulation in mixed heterogeneous mouse mammary tumors. Cancer Res., 48: 5747-5753, 1988.